Novartis’s Erelzi cleared in Europe

Novartis ahs won European clerance for its biosimilar Erelzi, as the European Commission approved it for Novartis’s division Sandoz.

Erelzi got approval for use in all indications of the reference medicine, Amgen’s Enbrel, Novarits said on Tuesday.

“Immunology is a priority for us and today’s approval of Erelzi, the second in this therapy area in as many weeks, clearly demonstrates our commitment to patients. This can also be seen in the progress we are making in our immunology pipeline with two recent file acceptances in Europe” said Carol Lynch, Global Head, Biopharmaceuticals, Sandoz. “As part of the wider Novartis immunology portfolio, Erelzi further expands the offering to healthcare professionals and patients in Europe. Its availability is expected to result in more patients being treated with much-needed biologics.”

Erelzi is approved for rheumatoid arthritis, axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis, and psoriatic arthritis, as well as juvenile idiopathic arthritis and pediatric plaque psoriasis. Erelzi is available in a pre-filled syringe and an auto-injector pen, SensoReady, which has been designed for patient safety, comfort, and convenience.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.